Table 1 Baseline characteristics of treatment-naive Japanese SLE patients
n = 40 patients | Â |
|---|---|
Female, n (%) | 37 (93) |
Age of onset, median (IQR), years | 31 (24–43) |
Observation period, median (IQR), years | 7.1 (2.8–9.6) |
Numbers of ACR-1997 criteria domains, median (IQR), n | 5 (4–6) |
ACR-1997 criteria domains, n (%) | |
 Malar rash | 19 (48) |
 Discoid rash | 6 (15) |
 Photosensitivity | 11 (28) |
 Oral ulcer | 6 (15) |
 Arthritis | 24 (60) |
 Serositis | 8 (20) |
 Renal disorder | 17 (43) |
 Neurologic disorder | 3 (8) |
 Hematologic disorder | 35 (88) |
 Immunologic disorder | 40 (100) |
 ANA positive | 40 (100) |
Auto-antibody profile, n (%) | |
 Anti-dsDNA positive | 36 (90) |
 Anti-U1-RNP positive | 24 (60) |
 Anti-Sm positive | 17 (43) |
 Anti-Ro/SS-A positive | 27 (68) |
 Anti-La/SS-B positive | 9 (23) |
 Lupus anticoagulant positive | 12 (30) |
 Anti-cardiolipin positive | 19 (48) |
C3, median (IQR), mg/dl | 42.5 (28.5–61.8) |
C4, median (IQR), mg/dl | 5.5 (3.3–11.8) |
SLEDAI-2K, median (IQR), score | 11 (8–16) |
Induction dose of prednisolone, median (IQR), mg/day | 40 (30–50) |
Methylprednisolone pulse, n (%) | 3 (8) |
IVCY, n (%) | 8 (20) |
MMF, n (%) | 7 (18) |
HCQ, n (%) | 5 (13) |
CNIs, n (%) | 4 (10) |